
Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 15 May 2023Portfolio NewsTherini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
- 1 May 2023Portfolio NewsAstellas Pharma buys Iveric Bio for $5.9 billion
- 27 April 2023Portfolio NewsTherini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
- 18 April 2023Portfolio NewsNitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting
- 6 April 2023Portfolio NewsQurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
- 28 March 2023Portfolio NewsBicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
- 28 March 2023Portfolio NewsPrilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease
- 9 March 2023Portfolio NewsALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
- 9 March 2023Portfolio NewsQurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
- 6 March 2023Portfolio NewsEyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team
- 23 February 2023Portfolio NewsAviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology
- 23 February 2023Portfolio NewsPrilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study